Data presented at the International Society of Paediatric Oncology (SIOP) Congress show Palonosetron is a valuable option for treating pediatric patie
The data presented at the SIOP congress in Toronto, 22-24 October, today, October 23rd derive from a large randomized trial.
Lugano, Switzerland, November 18, 2014 – Helsinn Group, the company focused on building quality cancer care, is pleased to announce that Riccardo Braglia, Helsinn’s Chief Executive Officer, is scheduled to present at the Jefferies 2014 Global Healthcare Conference on Wednesday, 19 November, 2014 at 17:00 GMT. The conference will be held at the Waldorf Hilton Hotel, Aldwych, London.
Mr. Braglia will give an overview of the Helsinn group, its pipeline of products, corporate goals and near and long-term opportunities.
The presentation will be webcast live and can be accessed for 90 days following the live presentation, via the following link:
Helsinn CEO Riccardo Braglia to present at the Jefferies 2014 Healthcare Conference About the Helsinn Group
Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the United States and a representative office in China. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.
Helsinn Group in‐licenses early‐to‐late stage new chemical entities, completing their development by performing preclinical and clinical studies and associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn’s products are out‐licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn’s products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers.
Further information on Helsinn Group is available at www.helsinn.com
For more information please contact:
Head of Communication & Press Office
Tel: +41 91-985-21-21
For media / external inquiries
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Matthew Neal /Laura Thornton
Tel: +44 (0)203 709 5700
Helsinn CEO Riccardo Braglia to present at the Jefferies 2014 Healthcare Conference